Laboratory tests are useful in diagnosing rheumatic diseases, but clinicians should be aware of the limitations of these tests. This article uses case vignettes to provide practical and evidence-based guidance on requesting and interpreting selected tests, including rheumatoid factor, anticitrullinated peptide antibody, antinuclear antibody, antiphospholipid antibodies, antineutrophil cytoplasmic antibody, and human leukocyte antigen-B27.
L
aboratory tests are often ordered inappropriately for patients in whom a rheumatologic illness is suspected; this occurs in both primary and secondary care. 1 Some tests are available both singly and as part of a battery of tests screening healthy people without symptoms.
The problem: negative test results are by no means always reassuring, and falsepositive results raise the risks of unnecessary anxiety for patients and clinicians, needless referrals, and potential morbidity due to further unnecessary testing and exposure to wrong treatments. 2 Clinicians should be aware of the pitfalls of these tests in order to choose them wisely and interpret the results correctly.
This article provides practical guidance on requesting and interpreting some common tests in rheumatology, with the aid of case vignettes.
■ RHEUMATOID FACTOR AND ANTICITRULLINATED PEPTIDE ANTIBODY
A 41-year-old woman, previously in good health, presents to her primary care practitioner with a 6-week history of pain and swelling in her hands and early morning stiffness lasting about 2 hours. She denies having any extraarticular symptoms. Physical examination reveals synovitis across her right metacarpophalangeal joints, proximal interphalangeal joint of the left middle fi nger, and left wrist. The primary care physician is concerned that her symptoms might be due to rheumatoid arthritis.
Would testing for rheumatoid factor and anticitrullinated peptide antibody be useful in this patient?

SURESH
Rheumatoid factor is an antibody (immunoglobulin M, IgG, or IgA) targeted against the Fc fragment of IgG. 3 It was so named because it was originally detected in patients with rheumatoid arthritis, but it is neither sensitive nor specifi c for this condition. A meta-analysis of more than 5,000 patients with rheumatoid arthritis reported that rheumatoid factor testing had a sensitivity of 69% and specifi city of 85%. 4 Numerous other conditions can be associated with a positive test for rheumatoid factor ( Table 1) . Hence, a diagnosis of rheumatoid arthritis cannot be confi rmed with a positive result alone, nor can it be excluded with a negative result.
Anticitrullinated peptide antibody, on the other hand, is much more specifi c for rheumatoid arthritis (95%), as it is seldom seen in other conditions, but its sensitivity is similar to that of rheumatoid factor (68%). [4] [5] [6] A positive result would thus lend strength to the diagnosis of rheumatoid arthritis, but a negative result would not exclude it.
Approach to early arthritis
When faced with a patient with early arthritis, some key questions to ask include 7, 8 : Is this an infl ammatory or a mechanical problem? Infl ammatory arthritis is suggested by joint swelling that is not due to trauma or bony hypertrophy, early morning stiffness lasting longer than 30 minutes, and elevated infl ammatory markers (erythrocyte sedimentation rate or C-reactive protein). Involvement of the small joints of the hands and feet may be suggested by pain on compression of the metacarpophalangeal and metatarsophalangeal joints, respectively.
Is there a defi nite identifi able underlying cause for the infl ammatory arthritis? The pattern of development of joint symptoms or the presence of extraarticular symptoms may suggest an underlying problem such as gout, psoriatic arthritis, systemic lupus erythematosus, or sarcoidosis.
If the arthritis is undifferentiated (ie, there is no defi nite identifi able cause), is it likely to remit or persist? This is perhaps the most important question to ask in order to prognosticate. Patients with risk factors for persistent disease, ie, for development of rheumatoid arthritis, should be referred to a rheumatologist early for timely institution of disease-modifying antirheumatic drug therapy. 9 Multiple studies have shown that patients in whom this therapy is started early have much better clinical, functional, and radiologic outcomes than those in whom it is delayed. [10] [11] [12] The revised American College of Rheumatology and European League Against Rheumatism criteria 13 include the following factors as predictors of persistence:
• Number of involved joints (with greater weight given to involvement of small joints) • Duration of symptoms 6 weeks or longer • Elevated acute-phase response (erythrocyte sedimentation rate or C-reactive protein level) • A positive serologic test (either rheumatoid factor or anticitrullinated peptide antibody). If both rheumatoid factor and anticitrullinated peptide antibody are positive in a patient with early undifferentiated arthritis, the risk of progression to rheumatoid arthritis is The frequency rises with age (5% at age 50, rising to 10% to 25% at age 70.
Data from reference 3.
almost 100%, thus underscoring the importance of testing for these antibodies. 5, 6 Referral to a rheumatologist should, however, not be delayed in patients with negative test results (more than one-third of patients with rheumatoid arthritis may be negative for both), and should be considered in those with infl ammatory joint symptoms persisting longer than 6 weeks, especially with involvement of the small joints (sparing the distal interphalangeals) and elevated acute-phase response.
Rheumatoid factor in healthy people without symptoms
In some countries, testing for rheumatoid factor is offered as part of a battery of screening tests in healthy people who have no symptoms, a practice that should be strongly discouraged.
Multiple studies, both prospective and retrospective, have demonstrated that both rheumatoid factor and anticitrullinated peptide antibody may be present several years before the clinical diagnosis of rheumatoid arthritis. 6, [14] [15] [16] But the risk of developing rheumatoid arthritis for asymptomatic individuals who are rheumatoid factor-positive depends on the rheumatoid factor titer, positive family history of rheumatoid arthritis in fi rst-degree relatives, and copresence of anticitrullinated peptide antibody. The absolute risk, nevertheless, is still very small. In some, there might be an alternative explanation such as undiagnosed Sjögren syndrome or hepatitis C.
In any event, no strategy is currently available that is proven to prevent the development of rheumatoid arthritis, and there is no role for disease-modifying therapy during the preclinical phase.
16
Back to our patient Blood testing in our patient reveals normal complete blood cell counts, aminotransferase levels, and serum creatinine concentration; fi ndings on urinalysis are normal. Her erythrocyte sedimentation rate is 56 mm/hour (reference range 0-15), and her C-reactive protein level is 26 mg/dL (normal < 3). Testing is negative for rheumatoid factor and anticitrullinated peptide antibody.
Although her rheumatoid factor and anticitrullinated peptide antibody tests are negative, she is referred to a rheumatologist because she has predictors of persistent disease, ie, symptom duration of 6 weeks, involvement of the small joints of the hands, and elevated erythrocyte sedimentation rate and C-reactive protein. The rheumatologist checks her parvovirus serology, which is negative.
The patient is given parenteral depot corticosteroid therapy, to which she responds briefl y. Because her symptoms persist and continue to worsen, methotrexate treatment is started after an additional 6 weeks.
■ ANTINUCLEAR ANTIBODY
A 37-year-old woman presents to her primary care physician with the complaint of tiredness. She has a family history of systemic lupus erythematosus in her sister and maternal aunt. She is understandably worried about lupus because of the family history and is asking to be tested for it.
Would testing for antinuclear antibody be reasonable?
Antinuclear antibody is not a single antibody but rather a family of autoantibodies that are directed against nuclear constituents such as single-or double-stranded deoxyribonucleic acid (dsDNA), histones, centromeres, proteins complexed with ribonucleic acid (RNA), and enzymes such as topoisomerase. 17, 18 Protein antigens complexed with RNA and some enzymes in the nucleus are also known as extractable nuclear antigens (ENAs). They include Ro, La, Sm, Jo-1, RNP, and ScL-70 and are named after the patient in whom they were fi rst discovered (Robert, Lavine, Smith, and John), the antigen that is targeted (ribonucleoprotein or RNP), and the disease with which they are associated (anti-ScL-70 or antitopoisomerase in diffuse cutaneous scleroderma).
Antinuclear antibody testing is commonly requested to exclude connective tissue diseases such as lupus, but the clinician needs to be aware of the following points: Antinuclear antibody might also be produced by the healthy immune system from time to time to clear the nuclear debris that is extruded from aging cells.
A study in healthy individuals 20 reported a prevalence of positive antinuclear antibody of 32% at a titer of 1/40, 15% at a titer of 1/80, 7% at a titer of 1/160, and 3% at a titer of 1/320. Importantly, a positive result was more common among family members of patients with autoimmune connective tissue diseases. 21 Hence, a positive antinuclear antibody result does not always mean lupus.
Antinuclear antibody testing is highly sensitive for lupus
With current laboratory methods, antinuclear antibody testing has a sensitivity close to 100%. Hence, a negative result virtually rules out lupus.
Two methods are commonly used to test for antinuclear antibody: indirect immunofl uorescence and enzyme-linked immunosorbent assay (ELISA). 22 While human epithelial (Hep2) cells are used as the source of antigen in immunofl uorescence, purifi ed nuclear antigens coated on multiple-well plates are used in ELISA.
Although ELISA is simpler to perform, immunofl uorescence has a slightly better sensitivity (because the Hep2 cells express a wide range of antigens) and is still considered the gold standard. As expected, the higher sensitivity occurs at the cost of reduced specifi city (about 60%), so antinuclear antibody will also be detected in all the other conditions listed above. 23 To improve the specifi city of antinuclear antibody testing, laboratories report titers (the highest dilution of the test serum that tested positive); a cutoff of greater than 1/80 is generally considered signifi cant.
Do not order antinuclear antibody testing indiscriminately
If the antinuclear antibody test is requested indiscriminately, the positive predictive value for the diagnosis of lupus is only 11%. 24 The test should be requested only when the pretest probability of lupus or other connective tissue disease is high. The positive predictive value is much higher in patients presenting with clinical or laboratory manifestations involving 2 or more organ systems ( Table 2) . 18, 25 Test for antinuclear antibody only in patients with involvement of multiple organ systems 
Clinical and laboratory manifestations of systemic lupus erythematosus
Pathogenesis
Examples of disease manifestations
Nonspecifi c infl ammatory response
Fever, fatigue, arthralgia, weight loss, anemia of chronic disease, elevated erythrocyte sedimentation rate
Immune complex deposition (commonly in the synovium, skin, serosa, kidneys, and lungs)
Infl ammatory arthritis, photosensitive skin rashes, pleurisy, pericarditis, glomerulonephritis, pneumonitis, or interstitial lung disease
Direct antibody-mediated attack
Hemolytic anemia (red cell antibodies), thrombocytopenia (antiplatelet antibodies), lymphopenia (lymphocytotoxic antibodies), neuropsychiatric manifestations such as depression and psychosis (antiribosomal P antibodies)
Associated features
Recurrent thrombosis and miscarriages (antiphospholipid syndrome), dry eyes and mouth (Sjögren syndrome)
Laboratory clues
Hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia, elevated erythrocyte sedimentation rate, normal C-reactive protein, low complement (due to immune complex formation), and abnormal urinalysis (proteinuria, hematuria, red cell casts, or dysmorphic red cells)
RHEUMATOLOGIC TESTS
Categorization of the specifi c antigen target improves disease specifi city. The antinuclear antibody in patients with lupus may be targeted against single-or double-stranded DNA, histones, or 1 or more of the ENAs. Among these, the presence of anti-dsDNA or anti-Sm is highly specifi c for a diagnosis of lupus (close to 100%). Neither is sensitive for lupus, however, with anti-dsDNA present in only 60% of patients with lupus and anti-Sm in about 30%. 17 Hence, patients with a positive antinuclear antibody and negative antidsDNA and anti-Sm may continue to pose a diagnostic challenge. Other examples of specifi c disease associations are listed in Table 3 .
To sum up, the antinuclear antibody test should be requested only in patients with involvement of multiple organ systems. Although a negative result would make it extremely unlikely that the clinical presentation is due to lupus, a positive result is insuffi cient on its own to make a diagnosis of lupus.
Diagnosing lupus is straightforward when patients present with a specifi c manifestation such as infl ammatory arthritis, photosensitive skin rash, hemolytic anemia, thrombocytopenia, or nephritis, or with specifi c antibodies such as those against dsDNA or Sm. Patients who present with nonspecifi c symptoms such as arthralgia or tiredness with a positive antinuclear antibody and negative anti-dsDNA and anti-Sm may present diffi culties even for the specialist. [25] [26] [27] Back to our patient Our patient denies arthralgia. She has no extraarticular symptoms such as skin rashes, oral ulcers, sicca symptoms, muscle weakness, Raynaud phenomenon, pleuritic chest pain, or breathlessness. Findings on physical examination and urinalysis are unremarkable.
Her primary care physician decides to check her complete blood cell count, erythrocyte sedimentation rate, and thyroid-stimulating hormone level. Although she is reassured that her tiredness is not due to lupus, she insists on getting an antinuclear antibody test.
Her complete blood cell counts are normal. Her erythrocyte sedimentation rate is 6 mm/hour. However, her thyroid-stimulating hormone level is elevated, and subsequent testing shows low free thyroxine and positive thyroid peroxidase antibodies. The antinuclear antibody is positive in a titer of 1/80 and negative for anti-dsDNA and anti-ENA.
We explain to her that the positive antinuclear antibody is most likely related to her autoimmune thyroid disease. She is referred to an endocrinologist.
■ ANTIPHOSPHOLIPID ANTIBODIES
A 24-year-old woman presents to the emergency department with acute unprovoked deep vein thrombosis in her right leg, confi rmed by ultrasonography. She has no history of previous thrombosis, and the relevant family history is unremarkable. She has never been pregnant. Her platelet count is 84 × 10 9 /L (reference range 150-400), and her baseline activated partial thromboplastin time is prolonged at 62 seconds (reference range 23.0-32.4). The rest of her blood counts and her prothrombin time, liver enzyme levels, and serum creatinine level are normal.
Should this patient be tested for antiphospholipid antibodies?
Antiphospholipid antibodies are important because of their association with thrombotic risk (both venous and arterial) and pregnancy morbidity. The name is a misnomer, as these antibodies are targeted against some proteins that are bound to phospholipids and not only to the phospholipids themselves.
According to the modifi ed Sapporo criteria for the classifi cation of antiphosphoAntiphospholipid antibodies may be present in 1% to 5% of apparently health people 
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Anticardiolipin antibodies Anticardiolipin (aCL) antibodies may be targeted either against beta-2 glycoprotein I (beta-2GPI) that is bound to cardiolipin (a phospholipid) or against cardiolipin alone; the former is more specifi c. Antibodies directed against cardiolipin alone are usually transient and are associated with infections and drugs. The result is considered signifi cant only when anticardiolipin antibodies are present in a medium to high titer (> 40 IgG phospholipid units or IgM phospholipid units, or > 99th percentile).
Lupus anticoagulant
The antibody with "lupus anticoagulant activity" is targeted against prothrombin plus phospholipid or beta-2GPI plus phospholipid. The test for it is a functional assay involving 3 steps:
Demonstrating the prolongation of a phospholipid-dependent coagulation assay like the activated partial thromboplastin time (aPTT). (This may explain the prolongation of aPTT in the patient described in the vignette.) Although the presence of lupus anticoagulant is associated with thrombosis, it is called an "anticoagulant" because of this in vitro prolongation of phospholipid-dependent coagulation assays.
Mixing study. The phospholipid-dependent coagulation assay could be prolonged because of either the defi ciency of a coagulation factor or the presence of the antiphospholipid antibodies. This can be differentiated by mixing the patient's plasma with normal plasma (which will have all the clotting factors) in a 1:1 ratio. If the coagulation assay remains prolonged after the addition of normal plasma, clotting factor defi ciency can be excluded.
Addition of a phospholipid. If the prolongation of the coagulation assay is due to the presence of an antiphospholipid antibody, addition of extra phospholipid will correct this.
Beta-2 glycoprotein I antibody (anti-beta-2GPI)
The beta-2GPI that is not bound to the cardiolipin can be detected by separately testing for beta-2GPI (the anticardiolipin test only detects the beta-2GPI that is bound to the cardiolipin). The result is considered significant if beta-2GPI is present in a medium to high titer (> 99th percentile).
Studies have shown that antiphospholipid antibodies may be present in 1% to 5% of apparently healthy people in the general population. 31 These are usually low-titer anticardiolipin or anti-beta-GPI IgM antibodies that are not associated with thrombosis or adverse pregnancy outcomes. Hence, the term antiphospholipid syndrome should be reserved for those who have had at least 1 episode of thrombosis or pregnancy morbidity and persistent antiphospholipid antibodies, and not those who have asymptomatic or transient antiphospholipid antibodies.
Triple positivity (positive anticardiolipin, lupus anticoagulant, and anti-beta-2GPI) seems to be associated with the highest risk of thrombosis, with a 10-year cumulative incidence of 37.1% (95% confi dence interval [CI] 19.9-54.3) for a fi rst thrombotic event, 32 and 44.2% (95% CI 38.6-49.8) for recurrent thrombosis. 33 The association with thrombosis is stronger for lupus anticoagulant than with the other 2 antibodies, with different studies 34 fi nding an odds ratio ranging from 5 to 16. A positive lupus anticoagulant test with or without a moderate to high titer of anticardiolipin or anti-beta-2GPI IgM or IgG constitutes a highrisk profi le, while a moderate to high titer of anticardiolipin or anti-beta-2GPI IgM or IgG constitutes a moderate-risk profi le. A low titer of anticardiolipin or anti-beta-2GPI IgM or IgG constitutes a low-risk profi le that may not be associated with thrombosis. 35 Antiphospholipid syndrome is important to recognize because of the need for long-term anticoagulation to prevent recurrence. 36 It may be primary, when it occurs on its own, or secondary, when it occurs in association with another autoimmune disease such as lupus.
Venous events in antiphospholipid syndrome most commonly manifest as lower-limb deep vein thrombosis or pulmonary embolism, while arterial events most commonly manifest as stroke or transient ischemic attack. 37 Obstetric manifestations may include not only miscarriage and stillbirth, but also preterm delivery, intrauterine growth retardation, and preeclampsia, all occurring due to placental insuffi ciency.
The frequency of antiphospholipid antibodies has been estimated as 13.5% in patients with stroke, 11% with myocardial infarction, 9.5% with deep vein thrombosis, and 6% for those with pregnancy morbidity. 38 Some noncriteria manifestations have also been recognized in antiphospholipid syndrome, such as thrombocytopenia, cardiac vegetations (Libman-Sachs endocarditis), livedo reticularis, and nephropathy.
The indications for antiphospholipid antibody testing are listed in Table 4 . 29 For the patient described in the vignette, it would be appropriate to test for antiphospholipid antibodies because of her unprovoked thrombosis, thrombocytopenia, and prolonged aPTT. Anticoagulant treatment is known to be associated with false-positive lupus anticoagulant, so any blood samples should be drawn before such treatment is commenced.
Back to our patient Our patient's anticardiolipin IgG test is negative, while her lupus anticoagulant and beta-2GPI IgG are positive. She has no clinical or laboratory features suggesting lupus.
She is started on warfarin. After 3 months, the warfarin is interrupted for several days, and she is retested for all 3 antiphospholipid antibodies. Her beta-2GPI I IgG and lupus anticoagulant tests are again positive. Because of the persistent antiphospholipid antibody positivity and clinical history of deep vein thrombosis, her condition is diagnosed as primary antiphospholipid syndrome. She is advised to continue anticoagulant therapy indefi nitely.
■ ANTINEUTROPHIL CYTOPLASMIC ANTIBODY
A 34-year-old man who is an injecting drug user presents with a 2-week history of fever, malaise, and generalized arthralgia. There are no localizing symptoms of infection. Notable fi ndings on examination include a temperature of 38.0°C (100.4°F), needle track marks in his arms, nonblanching vasculitic rash in his legs, and a systolic murmur over the precordium. His white blood cell count is 15.3 × 10 9 /L (reference range 3.7-11.0), and his C-reactive protein level is 234 mg/dL (normal < 3). Otherwise, results of blood cell counts, liver enzyme tests, renal function tests, urinalysis, and chest radiography are normal.
Two sets of blood cultures are drawn. Transthoracic echocardiography and the antineutrophil cytoplasmic antibody (ANCA) test are requested, as are screening tests for human immunodefi ciency virus, hepatitis B, and hepatitis C.
Was the ANCA test indicated in this patient?
ANCAs are autoantibodies against antigens Knowledge of the antiphospholipid antibody status helps to decide if low-dose aspirin should be recommended for primary prevention of thrombosis. 32 Lupus anticoagulant is likely to be falsely positive in those with acute thrombosis and those receiving anticoagulant therapy. Hence, anticoagulant therapy should be interrupted for at least 7 days before testing for lupus anticoagulant. However, anticardiolipin and anti-beta-2 glycoprotein I can be tested at any time, as they are not affected by thrombosis or anticoagulant therapy. SURESH located in the cytoplasmic granules of neutrophils and monocytes. They are associated with small-vessel vasculitides such as granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and isolated pauciimmune crescentic glomerulonephritis, all collectively known as ANCA-associated vasculitis (AAV). Indirect immunofl uorescence does not give information about the exact antigen that is targeted; this can only be obtained by performing 1 of the antigen-specifi c immunoassays. The target antigen for c-ANCA is usually proteinase-3 (PR3), while that for p-ANCA could be myeloperoxidase (MPO), cathepsin, lysozyme, lactoferrin, or bactericidal permeability inhibitor. Anti-PR3 is highly specifi c for GPA, while anti-MPO is usually associated with MPA and EGPA. Less commonly, anti-PR3 may be seen in patients with MPA and anti-MPO in those with GPA. Hence, there is an increasing trend toward classifying ANCA-associated vasculitis into PR3-associated or MPO-associated vasculitis rather than as GPA, MPA, EGPA, or renal-limited vasculitis. 40 Several audits have shown that the ANCA test is widely misused and requested indiscriminately to rule out vasculitis. This results in a lower positive predictive value, possible harm to patients due to increased falsepositive rates, and increased burden on the laboratory. [41] [42] [43] At least 2 separate groups have demonstrated that a gating policy that refuses ANCA testing in patients without clinical evidence of systemic vasculitis can reduce the number of inappropriate requests, improve the diagnostic yield, and make it more clinically relevant and cost-effective. 44, 45 The clinician should bear in mind that: ANCA testing should be requested only if the pretest probability of ANCA-associated vasculitis is high. The indications proposed by the International Consensus Statement on ANCA testing 46 are listed in Table 5 . These criteria have been clinically validated, with 1 study even demonstrating that no cases of ANCA-associated vasculitis would be missed if these guidelines are followed.
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Current guidelines recommend using one of the antigen-specifi c assays for PR3 and MPO as the primary screening method. 48 Until recently, indirect immunofl uorescence was used to screen for ANCA-associated vasculitis, and positive results were confi rmed by ELISA to detect ANCAs specifi c for PR3 and MPO, 49 but this is no longer recommended because of recent evidence suggesting a large variability between the different indirect immunofl uorescent methods and improved diagnostic performance of the antigen-specifi c assays.
In a large multicenter study by Damoiseaux et al, the specifi city with the different antigen-specifi c immunoassays was 98% to 99% for PR3-ANCA and 96% to 99% for MPO-ANCA. ANCA-associated vasculitis should not be considered excluded if the PR3 and MPO-ANCA are negative. In the Damoiseaux study, about 11% to 15% of patients with GPA and 8% to 24% of patients with MPA tested negative for both PR3 and MPO-ANCA. 50 If the ANCA result is negative and clinical suspicion for ANCA-associated vasculitis is high, the clinician may wish to consider requesting another immunoassay method or indirect immunofl uorescence. Results of indirect immunofl uorescent testing results may be positive in those with a negative immunoassay, and vice versa.
A positive ANCA result is not diagnostic of ANCA-associated vasculitis. Numerous other conditions are associated with ANCA, usually p-ANCA or atypical ANCA ( Table  6 ). The antigens targeted by these ANCAs are usually cathepsin, lysozyme, lactoferrin, and bactericidal permeability inhibitor.
Thus, the ANCA result should always be interpreted in the context of the whole clinical picture. 51 Biopsy should still be considered the gold standard for the diagnosis of AN-CA-associated vasculitis. The ANCA titer can help to improve clinical interpretation, because the likelihood of ANCA-associated vasculitis increases with higher levels of PR3 and MPO-ANCA.
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Back to our patient Our patient's blood cultures grow methicillinsensitive Staphylococcus aureus in both sets after 48 hours. Transthoracic echocardiography reveals vegetations around the tricuspid valve, with no evidence of valvular regurgitation. The diagnosis is right-sided infective endocarditis. He is started on appropriate antibiotics.
Tests for human immunodefi ciency virus, hepatitis B, and hepatitis C are negative. The ANCA test is positive for MPO-ANCA at 28 IU/mL (normal < 10).
The positive ANCA is thought to be related to the infective endocarditis. His vasculitis is most likely secondary to infective endocarditis and not ANCA-associated vasculitis. The ANCA test need not have been requested in the fi rst place.
■ HUMAN LEUKOCYTE ANTIGEN-B27
A 22-year-old man presents to his primary care physician with a 4-month history of gradually worsening low back pain associated with early morning stiffness lasting more than 2 hours. He has no peripheral joint symptoms.
In the last 2 years, he has had 2 separate episodes of uveitis. There is a family history of ankylosing spondylitis in his father. Examination reveals global restriction of lumbar movements but is otherwise unremarkable. Magnetic resonance imaging (MRI) of the lumbar spine and sacroiliac joints is normal.
Should this patient be tested for human leukocyte antigen-B27 (HLA-B27)?
The major histocompatibility complex (MHC) is a gene complex that is present in all animals. It encodes proteins that help with immunologic tolerance. HLA simply refers to the human version of the MHC. 53 The HLA gene complex, located on chromosome 6, is HLA-B27 is strongly associated with ankylosing spondylitis, also known as axial spondyloarthropathy. 54 Other genes also contribute to the pathogenesis of ankylosing spondylitis, but HLA-B27 is present in more than 90% of patients with this disease and is by far considered the most important. The association is not as strong for peripheral spondyloarthropathy, with studies reporting a frequency of up to 75% for reactive arthritis and infl ammatory bowel disease-associated arthritis, and up to 50% for psoriatic arthritis and uveitis. 55 About 9% of healthy, asymptomatic individuals may have HLA-B27, so the mere presence of this gene is not evidence of disease. 56 There may be up to a 20-fold increased risk of ankylosing spondylitis among those who are HLA-B27-positive.
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Some HLA genes have many different alleles, each of which is given a number (explaining the number 27 that follows the B). Closely related alleles that differ from one another by only a few amino-acid substitutions are then categorized together, thus accounting for more than 100 subtypes of HLA-B27 (designated from HLA-B*2701 to HLA-B*27106). These subtypes vary in frequency among different racial groups, and the population prevalence of ankylosing spondylitis parallels the frequency of HLA-B27. 58 The most common subtype seen in white people and American Indians is B*2705. HLA-B27 is rare in blacks, explaining the rarity of ankylosing spondylitis in this population. Further examples include HLA-B*2704, which is seen in Asians, and HLA-B*2702, seen in Mediterranean populations. Not all subtypes of HLA-B27 are associated with disease, and some, like HLA-B*2706, may also be protective.
When should the clinician consider testing for HLA-B27? Not all patients with low back pain need an HLA-B27 test. First, it is important to look for clinical features of axial spondyloarthropathy ( Table 7) . The unifying feature of spondyloarthropathy is enthesitis (infl ammation at the sites of insertion of tendons or ligaments on the skeleton). Infl ammation of axial entheses causes spondylitis and sacroiliitis, manifesting as infl ammatory back pain. Clinical clues to infl ammatory back pain include insidious onset, aggravation with rest or inactivity, prolonged early morning stiffness, disturbed sleep during the second half of the night, relief with movement or activity, alternating gluteal pain (due to sacroiliitis), and good response to anti-infl ammatory medication (although nonspecifi c).
Peripheral spondyloarthropathy may present with arthritis, enthesitis (eg, heel pain due to infl ammation at the site of insertion of the Achilles tendon or plantar fascia), or dactylitis ("sausage" swelling of the whole fi nger or toe due to extension of infl ammation beyond the margins of the joint). Other clues may include psoriasis, infl ammatory bowel disease, history of preceding gastrointestinal or genitourinary infection, family history of similar conditions, and history of recurrent uveitis.
For the initial assessment of patients who have infl ammatory back pain, plain radiography of the sacroiliac joints is considered the gold standard. 59 If plain radiography does not show evidence of sacroiliitis, MRI of the sacroiliac joints should be considered. While plain radiography can reveal only structural changes such as sclerosis, erosions, and ankylosis, MRI is useful to evaluate for early infl ammatory changes such as bone marrow edema. Imaging the lumbar spine is not necessary, as the sacNot all patients with low back pain need an HLA-B27 test roiliac joints are almost invariably involved in axial spondyloarthropathy, and lesions seldom occur in the lumbar spine in isolation. 60 The diagnosis of ankylosing spondylitis previously relied on confi rmatory imaging features, but based on the new International Society classifi cation criteria, [61] [62] [63] which can be applied to patients with more than 3 months of back pain and age of onset of symptoms before age 45, patients can be classifi ed as having 1 of the following:
• Radiographic axial spondyloarthropathy, if they have evidence of sacroiliitis on imaging plus 1 other feature of spondyloarthropathy • Nonradiographic axial spondyloarthropathy, if they have a positive HLA-B27 plus 2 other features of spondyloarthropathy ( Table 7) . These new criteria have a sensitivity of 82.9% and specifi city of 84.4%. 62, 63 The disease burden of radiographic and nonradiographic axial spondyloarthropathy has been shown to be similar, suggesting that they are part of the same disease spectrum. Thus, the HLA-B27 test is useful to make a diagnosis of axial spondyloarthropathy even in the absence of imaging features and could be requested in patients with 2 or more features of spondyloarthropathy. In the absence of imaging features and a negative HLA-B27 result, however, the patient cannot be classifi ed as having axial spondyloarthropathy.
Back to our patient
The absence of radiographic evidence would not exclude axial spondyloarthropathy in our patient. The HLA-B27 test is requested because of the infl ammatory back pain and the presence of 2 spondyloarthropathy features (uveitis and the family history) and is reported to be positive. His disease is classifi ed as nonradiographic axial spondyloarthropathy.
He is started on regular naproxen and is referred to a physiotherapist. After 1 month, he reports signifi cant symptomatic improvement. He asks if he can be retested for HLA-B27 to see if it has become negative. We tell him that there is no point in repeating it, as it is a gene and will not disappear.
■ SUMMARY: CONSIDER THE CLINICAL PICTURE
When approaching a patient suspected of having a rheumatologic disease, a clinician should fi rst consider the clinical presentation and the intended purpose of each test. The tests, in general, might serve several purposes. They might help to: Increase the likelihood of the diagnosis in question. For example, a positive rheumatoid factor or anticitrullinated peptide antibody can help diagnose rheumatoid arthritis in a patient with early polyarthritis, a positive HLA-B27 can help diagnose ankylosing spondylitis in patients with infl ammatory back pain and normal imaging, and a positive ANCA can help diagnose ANCA-associated vasculitis in a patient with glomerulonephritis.
Reduce the likelihood of the diagnosis in question. For example, a negative antinuclear antibody test reduces the likelihood of lupus in a patient with joint pains.
Monitor the condition. For example DNA antibodies can be used to monitor the activity of lupus.
Plan the treatment strategy. For example, one might consider lifelong anticoagulation if antiphospholipid antibodies are persistently positive in a patient with thrombosis.
Prognosticate. For example, positive rheumatoid factor and anticitrullinated peptide antibody increase the risk of erosive rheumatoid arthritis.
If the test was requested in the absence of a clear indication and the result is positive, it is important to bear in mind the potential pitfalls associated with that test and not attach a diagnostic label prematurely. None of the tests can confi rm or exclude a condition, so the results should always be interpreted in the context of the whole clinical picture.
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